The Journal of Allergy and Clinical Immunology
Volume 120, Issue 1 , Pages 76-83, July 2007

IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain—containing protein tyrosine phosphatase 1

  • Alison Taylor, PhD

      Affiliations

    • From the Swiss Institute of Allergy and Asthma Research, Davos
    • School of Chemical Sciences and Pharmacy, University of East Anglia, Norwich
    • These authors contributed equally to this work.
  • ,
  • Mübeccel Akdis, MD, PhD

      Affiliations

    • From the Swiss Institute of Allergy and Asthma Research, Davos
    • These authors contributed equally to this work.
  • ,
  • Andrea Joss, PhD

      Affiliations

    • From the Swiss Institute of Allergy and Asthma Research, Davos
  • ,
  • Tunç Akkoç, PhD

      Affiliations

    • From the Swiss Institute of Allergy and Asthma Research, Davos
    • Department of Pediatric Allergology, Marmara University, Istanbul
  • ,
  • Renate Wenig, PhD

      Affiliations

    • Paul Ehrlich Institute, Langen
  • ,
  • Marco Colonna, MD

      Affiliations

    • Washington University School of Medicine, St Louis, Mo
  • ,
  • Isabelle Daigle, PhD

      Affiliations

    • From the Swiss Institute of Allergy and Asthma Research, Davos
  • ,
  • Egbert Flory, PhD

      Affiliations

    • Paul Ehrlich Institute, Langen
  • ,
  • Kurt Blaser, PhD

      Affiliations

    • From the Swiss Institute of Allergy and Asthma Research, Davos
  • ,
  • Cezmi A. Akdis, MD

      Affiliations

    • From the Swiss Institute of Allergy and Asthma Research, Davos
    • Corresponding Author InformationReprint requests: Cezmi A. Akdis, MD, Swiss Institute of Allergy and Asthma Research, Obere Strasse 22, CH-7270 Davos, Switzerland.

Received 13 November 2006; received in revised form 5 April 2007; accepted 6 April 2007. published online 26 May 2007.

Davos, Switzerland, Norwich, United Kingdom, Istanbul, Turkey, Langen, Germany, and St Louis, Mo

Background

Specific T-cell activation requires T-cell receptor stimulation and the generation of costimulatory signals. Major costimulatory signals are delivered to T cells by the interaction of CD28 and inducible costimulator (ICOS).

Objective

To investigate the molecular pathways involved in direct T-cell suppression by IL-10.

Methods

T-cell proliferation analysis, immunoprecipitations, and Western blots were performed after T-cell receptor and CD28 and ICOS stimulations in the absence or presence of IL-10. Dominant-negative src homology 2 domain–containing protein tyrosine phosphatase 1 (SHP-1) overexpression, small inhibitory RNA, and SHP-1–deficient and IL-10–deficient mice were used.

Results

IL-10 receptor–associated tyrosine kinase Tyk-2 acts as a constitutive reservoir for SHP-1 in resting T cells, and then tyrosine phosphorylates SHP-1 on IL-10 binding. SHP-1 rapidly binds to CD28 and ICOS costimulatory receptors and dephosphorylates them within minutes. In consequence, the binding of phosphatidylinositol 3-kinase to either costimulatory receptor no longer occurs, and downstream signaling is inhibited. Accordingly, spleen cells from SHP-1–deficient mice showed increased proliferation with CD28 and ICOS stimulation in comparison with wild-type mice, which was not suppressed by IL-10. Generation of dominant-negative SHP-1–overexpressing T cells or silencing of the SHP-1 gene by small inhibitory RNA both altered SHP-1 functions and abolished the T-cell suppressive effect of IL-10.

Conclusion

The rapid inhibition of the CD28 or ICOS costimulatory pathways by SHP-1 represents a novel mechanism for direct T-cell suppression by IL-10.

Clinical implications

Molecular mechanisms of direct T-cell suppression by IL-10 may provide a novel target for therapy of allergy/asthma and autoimmune disease.

Key words: IL-10, T cell, suppression, costimulation, anergy, SHP-1, phosphorylation, tolerance, inhibition

Abbreviations used: CFSE, Carboxyfluorescein succinimidyl ester, cRPMI, Complete Roswell Park Memorial Institute, DN, Dominant-negative, GALV, Gibbon ape leukemia virus, GFP, Green fluorescent protein, HA, Hemagglutinin, ICOS, Inducible costimulator, ITAM, Immunoreceptor tyrosine-based activation motif, ITIM, Immunoreceptor tyrosine-based inhibition motif, MLV, Moloney murine leukemia virus, NGFR, Nerve growth factor receptor, PI3-K, Phosphatidylinositol 3-kinase, PPD, Purified protein derivative, SEB, Staphylococcal enterotoxin B, SH2, Src-homology-2, SHP-1, Src homology 2 domain–containing protein tyrosine phosphatase 1, siRNA, Small inhibitory RNA, STAT, Signal transducer and activator of transcription, TCR, T-cell receptor

 

 Supported by Swiss National Science Foundation 32-112306 (M.A.) and 32-105865 (C.A.A.) and German Science foundation (E.F.) grants.Disclosure of potential conflict of interest: M. Akdis and C. A. Akdis have consulting arrangements with GlaxoSmithKline, 3M Pharma, and Aventis; have received grant support from ALK-Abelló, Stallergenes, Allergopharma, Essex Chemie, the Swiss National Science Foundation, and Ga2LEN; and are on the speakers' bureau for Stallergenes, Allergopharma, and Merck. K. Blaser has received grant support from the Swiss National Science Foundation and is employed by the Swiss Institute of Allergy and Asthma Research. The other authors have declared that they have no conflict of interest.

PII: S0091-6749(07)00757-9

doi:10.1016/j.jaci.2007.04.004

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 1 , Pages 76-83, July 2007